ALFA USA News
Straight from the SEC filing
Every SEC filing by First Tracks Biotherapeutics, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (15 Oct 2026). Not a valuation or a recommendation.
Down 6.3% over the last month ($38.47 on 15 Sep → $36.04 on 15 Oct). Daily closing prices. Source: Yahoo Finance.
| 15 Sep | $38.47 |
|---|---|
| 16 Sep | $39.00 |
| 17 Sep | $39.20 |
| 18 Sep | $38.60 |
| 21 Sep | $38.99 |
| 22 Sep | $41.03 |
| 23 Sep | $36.66 |
| 24 Sep | $35.83 |
| 25 Sep | $34.42 |
| 28 Sep | $36.65 |
| 29 Sep | $35.98 |
| 30 Sep | $35.44 |
| 1 Oct | $33.92 |
| 2 Oct | $33.28 |
| 5 Oct | $32.99 |
| 6 Oct | $31.39 |
| 7 Oct | $30.59 |
| 8 Oct | $32.01 |
| 9 Oct | $31.85 |
| 12 Oct | $34.05 |
| 13 Oct | $31.68 |
| 14 Oct | $34.13 |
| 15 Oct | $36.04 |
First Tracks Biotherapeutics (TRAX) enters into a $200 million private placement agreement at $32.75 per share to fund clinical development of its ANB033 program.
First Tracks Biotherapeutics (TRAX) rose 6.91% on positive Phase 1b results for ANB033 in Celiac Disease. The firm expects a cash runway through Q2 2028.
Track First Tracks Biotherapeutics, Inc. live
Get the next First Tracks Biotherapeutics, Inc. SEC filing seconds after it lands.
